Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15413021 | 0.84 | LMNA (0.47) | MEN1KMT2ALMNAMAPTNPC1 | |
| SCHEMBL6229358 | 0.81 | GAA (0.37) | MCL1LMNAMAPTGAANPSR1 | |
| SCHEMBL5762956 | 0.78 | KMT2A (0.44) | MCL1KMT2ALMNANPC1GAA | |
| SCHEMBL14356223 | 0.73 | PTGS2 (0.46) | LMNANPC1GAAMAPK1ALDH1A1 | |
| SCHEMBL5367871 | 0.73 | MCL1 (0.55) | MCL1MEN1KMT2ALMNAGAA | |
| SCHEMBL5763589 | 0.70 | ALDH1A1 (0.39) | MCL1KMT2ANPC1GAANPSR1 | |
| SCHEMBL15412587 | 0.70 | OGG1 (0.43) | MCL1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2276990 | 0.69 | MCL1 (0.56) | MCL1FFAR1MAPTPPARGPPARA | |
| SCHEMBL14958764 | 0.68 | TSHR (0.44) | MCL1LMNAMAPTGAAMAPK1 | |
| SCHEMBL2844790 | 0.67 | LMNA (0.56) | MEN1KMT2ALMNANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | MCL1 2875/4885MEN1 1242/4885KMT2A 2592/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MCL1 3190/4885MEN1 1915/4885KMT2A 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.